RecruitingPhase 3NCT03627013

Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)

A Prospective, Randomized, Single Blind, Multicentre Phase III Study on Organ Preservation With Custodiol-N Solution Compared With Custodiol Solution in Or-gan Transplantation (Kidney, Liver and Pancreas)


Sponsor

Dr. F. Köhler Chemie GmbH

Enrollment

362 participants

Start Date

May 23, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Synopsis Title of Study A prospective, randomized, single blind multicentre phase III study on organ preservation with Custodiol-N compared with Custodiol solution in organ transplantation (kidney, liver and pancreas) Protocol number: CL-N-KLP-TX-III/07-AT/17 Trial design The study design is a prospective, randomized, single blind, multicentre, phase III comparison study of organ perfusion intended to demonstrate non-inferiority of Custodiol-N against Custodiol in organ transplantation of kidney, combined kidney-pancreas and liver. Intended duration of study The overall duration for the trial is expected to be approximately 30 months. The du-ration of the trial for each subject is expected to be 3 months (transplantation and a follow-up period of 90 days). Purpose of the study The objective of this investigation is to demonstrate non-inferiority of graft preservation with Custodiol-N compared to Custodiol with respect to both graft function and injury after transplantation of kidney, liver or combined kidney-pancreas. Patient selection The study population will be selected from patients who will undergo kidney, liver or combined kidney-pancreas transplantation. Patients of each gender will be included in the study. Planned number of patients (recipients) In total N=362 including: Kidney 242 (including approx. 30 combined kidney-pancreas) Liver 120


Eligibility

Min Age: 18 Years

Inclusion Criteria11

  • All organs (kidney, combined kidney - pancreas and liver) Donor criteria
  • For All patients undergoing deceased donation:
  • \- deceased adult (≥18 years) donors fulfilling the criteria for organ donation
  • For All patients undergoing living kidney donation:
  • \- adult (≥18 years) living kidney donors fulfilling the criteria for organ donation
  • Patient (recipient) criteria
  • recipients awaiting their transplant
  • recipients ≥18 years
  • recipients' signed informed consent before the transplantation Kidney / combined kidney - pancreas recipients
  • n/a Liver recipient
  • full organ transplantation

Exclusion Criteria14

  • All organs (kidney, combined kidney - pancreas and liver) Donor criteria (not applicable for living kidney donors)
  • \- donors whose organs are all allocated out of retrieving study center
  • general refusal of organ donation
  • donation after cardiac death (DCD) Patient (recipient) criteria
  • pregnant or lactating patients
  • recipients participating in any interventional study (e.g. another study involving compound/interventions aimed at the reduction of preservation and / or ischemia / reperfusion injury)
  • all combined allocations other than pancreas and kidney
  • Kidney / combined kidney -pancreas recipient
  • double kidney transplantation
  • pancreas retransplantation
  • machine perfusion According to the KDIGO-Guidelines (2009) all patients with PRA \>0% are only included in the living donation setting.
  • Liver recipient
  • retransplantation
  • machine perfusion

Interventions

DRUGCustodiol-N Solution

Perfusion

DRUGCustodiol HTK Solution

Perfusion


Locations(4)

Medical University Graz

Graz, Austria

Medical University Innsbruck

Innsbruck, Austria

Ordensklinikum Linz

Linz, Austria

Medical University Vienna

Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03627013


Related Trials